NASDAQ:ANIK
Anika Therapeutics, Inc.
Anika Therapeutics, Inc.'s revenue fell 5.9% in fiscal 2025 to $112.8M while operating margin fell to −9.8%. Free cash flow was $4.4M, 3.9% of revenue, and the diluted share count fell 2.6%.Summary generated from Anika Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 3, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$112.8M
Revenue growth−5.9%
Revenue, 5-yr CAGR−2.9%
Gross margin56.6%
Operating margin−9.8%
Net margin−9.6%
ROICn/a
Return on equity−7.3%
Debt / equityn/a
Free cash flow$4.4M
FCF margin3.9%
Share count change−2.6%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 148 | 114 | 121 | 120 | 113 |
| Operating income | 3 | 4 | 1 | −5 | −11 |
| Net income | 4 | −15 | −83 | −56 | −11 |
| Free cash flow | 3 | −3 | −7 | −2 | 4 |
Recent filings
- 4Insider transaction report
Aug 5, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Jul 29, 2026 - 8-KResults of operations and financial condition
Jul 29, 2026 - 8-KEntry into a material agreement
Jul 14, 2026 - 4Insider transaction report
Jun 23, 2026 - 8-KDirector or officer change
Jun 23, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
Apr 30, 2026 - 8-KResults of operations and financial condition
Apr 29, 2026